In a patient with a partial or absent response to Concerta (methylphenidate extended‑release) 18 mg, should the dose be increased to 27 mg, or should the therapy be switched to Ritalin (methylphenidate immediate‑release) or to Focalin (dexmethylphenidate)?

Increase Concerta to 27 mg

When a patient has a partial or absent response to Concerta 18 mg, the most appropriate next step is to increase the dose to 27 mg rather than switching formulations. This follows the established principle of systematic dose titration within the same medication before considering alternative formulations or switching drug classes.

Rationale for Dose Escalation

The FDA label for Concerta explicitly states that "doses may be increased in 18 mg increments at weekly intervals for patients who have not achieved an optimal response at a lower dose," and specifically notes that "a 27 mg dosage strength is available for physicians who wish to prescribe between the 18 mg and 36 mg dosages" 1. This graduated titration approach is the standard of care.

The 2002 AACAP practice parameter reinforces this systematic approach, recommending that "if symptom control is not achieved, the dose generally should be increased in weekly increments of 5 to 10 mg per dose for MPH" 2. The landmark MTA study demonstrated that when a full range of methylphenidate doses is systematically trialed, more than 70% of children and adolescents with ADHD respond to methylphenidate 3. The key finding was that community treatment with lower doses and less systematic titration produced inferior results compared to optimal medication management with proper dose escalation.

Why Not Switch to Ritalin (Immediate-Release)?

Switching from Concerta (extended-release) to Ritalin (immediate-release) would be counterproductive for several reasons:

• Convenience and compliance: Extended-release formulations eliminate the need for midday dosing at school, which significantly improves adherence 2, 4
• Coverage duration: Concerta provides 12 hours of symptom control versus 3-4 hours for immediate-release methylphenidate 5
• Pharmacokinetic profile: You haven't yet explored the full therapeutic range of Concerta (18-72 mg for adolescents, 18-54 mg for children) 1

The evidence shows that switching from immediate-release to sustained-release methylphenidate often requires higher-than-equivalent doses for success—in one study, 55% of patients needed larger than recommended equivalent doses of Concerta for a successful switch 6. This suggests that if anything, patients may need more extended-release medication, not less.

Why Not Switch to Focalin (Dexmethylphenidate)?

While dexmethylphenidate (the d-isomer of methylphenidate) can provide comparable efficacy at approximately half the dose of racemic methylphenidate 7, 4, switching at this early stage is premature because:

• You haven't exhausted methylphenidate titration: The patient has only tried the lowest dose (18 mg) of Concerta, which has a therapeutic range up to 54-72 mg depending on age 1
• No clear advantage in partial responders: Dexmethylphenidate is pharmacologically similar to methylphenidate—it's simply the more active enantiomer. If there's a partial response to methylphenidate, increasing the dose is more logical than switching to what is essentially a refined version of the same molecule
• Reserve for true non-responders: Switching between stimulant families (methylphenidate vs. amphetamine) or formulations should be reserved for patients who fail to respond adequately after proper dose titration 2, 8

Clinical Algorithm

Step 1: Increase Concerta from 18 mg to 27 mg and reassess after 1 week 1

Step 2: If response remains inadequate, continue titrating in 18 mg increments weekly (27 mg → 36 mg → 54 mg for children; up to 72 mg for adolescents) 1

Step 3: Only after reaching the maximum tolerated dose within the therapeutic range without adequate response should you consider:

• Switching to amphetamine-based stimulants (which have a different mechanism and may work in methylphenidate non-responders) 3, 8
• Adding immediate-release methylphenidate for breakthrough symptoms in late afternoon/evening if Concerta wears off too early 6
• Considering dexmethylphenidate if tolerability issues emerge with higher methylphenidate doses

Important Caveats

• Monitor for side effects: Common adverse effects include decreased appetite, insomnia, and irritability. These may necessitate dose reduction or timing adjustments rather than switching medications 2, 9
• Assess adherence: Confirm the patient is actually taking the medication as prescribed before escalating dose 3
• Use objective measures: Employ standardized rating scales from both parents and teachers to objectively assess response, not just subjective impressions 2, 3
• Consider comorbidities: If anxiety, tics, or substance use concerns exist, non-stimulants (atomoxetine, guanfacine, clonidine) may be more appropriate first-line alternatives 10

The evidence consistently shows that systematic dose titration within the same stimulant formulation, with proper monitoring, yields the best outcomes before considering medication switches 2, 3, 1.